DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration announced that it will hold a 2015 year-end investor conference call on Thursday, December 17, 2015, at 4:30 p.m. Eastern Time. President and CEO Todd Cooper will host the conference call along with Randy Thurman, Executive Chairman of the Board. Interested parties can listen to the call via the following: INTERNET: Go to www.presbia.com at least 15 minutes prior to the st
Mundipharma Ophthalmology Products Limited has reached an agreement with Merck to acquire Merck’s glaucoma treatment portfolio in Australia, Canada, Latin America, the Middle East, Africa and New Zealand, the company announced in a press release.The portfolio includes Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), Cosopt preservative-free, Saflutan (tafluprost), Timoptic (timolol maleate ophthalmic solution), Timoptic XE, Timoptic preservative-free, Trusopt (dorzolamide hydrochloride ophthalmic solution) and Trusopt preservative-free.
Imprimis Pharmaceuticals reported $2.7 million in total revenue in the third quarter, a 508% increase from $0.4 million reported in the same quarter of 2014, according to a press release. Sales for Tri-Moxi and Tri-Moxi-Vanc compounded injectable formulations were reported at $594,000 in the third quarter. Sales for combination topical eye drop formulations were reported at $263,000.
(MedPage Today) — Growth attributed to coverage expansion under ACA and new hep C drugs
MAILAND–(BUSINESS WIRE)–Der rekombinante humane Nervenwachstumsfaktor (rhNGF) erhält vom „Ausschuss für Arzneimittel für seltene Leiden“ der Europäischen Arzneimittel-Agentur (EMA) den Orphan-Drug-Status bei der Behandlung der neurotrophen Keratopathie. Das von Dompé entwickelte und biotechnologisch hergestellte Molekül basiert auf den Forschungen der Nobelpreisträgerin Rita Levi Montalcini. NGF ist der erste neurotrophe Faktor, der identifiziert und isoliert werden konnte. Er zählt zu den in
MILÁN–(BUSINESS WIRE)–La empresa biofarmacéutica Dompé ha anunciado hoy que el Comité de Medicamentos Huérfanos de la Agencia Europea de Medicamentos ha designado oficialmente el factor de crecimiento nervioso humano recombinante (rhNFG) – la molécula de biotecnología en investigación desarrollada por Dompé de acuerdo con los estudios de la premio Nobel Rita Levi-Montalcini – como medicamento huérfano para el tratamiento de la queratitis neurotrófica. NGF es el primer factor neurotrófico que